Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

Basit Öğe Kaydı
dc.authoridYasin, Ayse Irem/0000-0002-1528-8065
dc.authoridOven, Bala Basak/0000-0002-9921-4089
dc.authoridAy, Seval/0000-0002-7555-2657
dc.authoridARIKAN, RUKIYE/0000-0003-2688-1515
dc.authoridDulgar, Ozgecan/0000-0002-0678-4024
dc.authoridTataroglu Ozyukseler, Deniz/0000-0002-0254-1084
dc.authoridBayram, Ertugrul/0000-0001-8713-7613
dc.authorwosidAy, Murat/GSI-4353-2022
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidYasin, Ayse Irem/HNR-8404-2023
dc.authorwosidmustafa, Muhammed/HME-1300-2023
dc.contributor.authorDulgar, Ozgecan
dc.contributor.authorOven, Basak Bala
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorArikan, Rukiye
dc.contributor.authorAy, Seval
dc.contributor.authorAyhan, Murat
dc.contributor.authorSelvi, Oguzhan
dc.date.accessioned2024-06-12T11:16:42Z
dc.date.available2024-06-12T11:16:42Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear. Materials and Methods We analyzed data of 160 consecutive patients with residual TNBC from eight cancer-center. Pathologic response was defined into two groups as having good-pathologic-response (MillerPayneGrading (MPG) IV-III) or poor-pathologic-response (MPG I-II). The characteristics of patients were compared regarding adjuvant capecitabine usage. Results Univariate-analysis revealed that age, histology, clinical-stage, tumor-size, lymph-nodes number, menopausal status, and pathological-stage were significantly different between two groups. In multivariate-analysis, menopausal status (p = 0.043) and residual tumor-size (p < 0.001) were found to be independent prognostic factors for pathological response. The hazard-ratio for disease recurrence and death in the poor-response group with adjuvant capecitabine was 2.94 (95% confidence-interval (CI), 1.21 to 7.10; p = 0.016) and 4.080 (95% CI, 1.22 to 13.64; p = 0.022), respectively. DFS (p = 0.58) and OS (p = 0.89) improvements with adjuvant capecitabine were not demonstrated in good-response groups. Conclusion This multicenter-study suggested that only the poor-response group to NAC achieved benefit from adjuvant capecitabine. Postmenopausal status and residual tumor-size were related to poor prognosis.en_US
dc.identifier.doi10.1080/14737140.2022.2076670
dc.identifier.endpage780en_US
dc.identifier.issn1473-7140
dc.identifier.issn1744-8328
dc.identifier.issue7en_US
dc.identifier.pmid35543015en_US
dc.identifier.scopus2-s2.0-85131384593en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage773en_US
dc.identifier.urihttps://doi.org/10.1080/14737140.2022.2076670
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24416
dc.identifier.volume22en_US
dc.identifier.wosWOS:000804681400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Review Of Anticancer Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTriple Negative Breast Canceren_US
dc.subjectNeoadjuvant Chemotherapy Responseen_US
dc.subjectPathological Responseen_US
dc.subjectResidual Tumor Sizeen_US
dc.subjectAdjuvant Capecitabineen_US
dc.subjectCyclophosphamideen_US
dc.subjectEpirubicinen_US
dc.subjectDocetaxelen_US
dc.titleIs the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu